https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20635 Sat 24 Mar 2018 07:55:47 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26115 12 years with a chronic cough of > 8 weeks' duration that was unexplained after systematic investigation and treatment were included and assessed for relevance and quality. Based on the systematic review, guideline suggestions were developed and voted on by using the American College of Chest Physicians organization methodology. Results: Eleven RCTs and five systematic reviews were included. The 11 RCTs reported data on 570 participants with chronic cough who received a variety of interventions. Study quality was high in 10 RCTs. The studies used an assortment of descriptors and assessments to identify UCC. Although gabapentin and morphine exhibited positive effects on cough-related quality of life, only gabapentin was supported as a treatment recommendation. Studies of inhaled corticosteroids (ICS) were affected by intervention fidelity bias; when this factor was addressed, ICS were found to be ineffective for UCC. Esomeprazole was ineffective for UCC without features of gastroesophageal acid reflux. Studies addressing nonacid gastroesophageal reflux disease were not identified. A multimodality speech pathology intervention improved cough severity. Conclusions: The evidence supporting the diagnosis and management of UCC is limited. UCC requires further study to establish agreed terminology and the optimal methods of investigation using established criteria for intervention fidelity. Speech pathology-based cough suppression is suggested as a treatment option for UCC. This guideline presents suggestions for diagnosis and treatment based on the best available evidence and identifies gaps in our knowledge as well as areas for future research.]]> Sat 24 Mar 2018 07:41:06 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29432 Sat 24 Mar 2018 07:39:23 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29176 Sat 24 Mar 2018 07:35:44 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36789 Mon 06 Jul 2020 11:38:40 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49491 4-weeks duration) and without underlying lung disease: (1) who do not havegastrointestinal GER symptoms, should empirical treatment for GERD be used? (2) withgastrointestinal GER symptoms, does treatment for GERD resolve the cough? (3) with orwithout gastrointestinal GER symptoms, what GER-based therapies should be used and forhow long? (4) if GERD is suspected as the cause, what investigations and diagnostic criteriabest determine GERD as the cause of the cough?METHODS:We used the CHEST Expert Cough Panel’s protocol and American College ofChest Physicians (CHEST) methodological guidelines and GRADE (Grading of Recom-mendations Assessment, Development and Evaluation) framework. Delphi methodology wasused to obtain consensus.RESULTS:Few randomized controlled trials addressed thefirst two questions and noneaddressed the other two. The single meta-analysis (two randomized controlled trials)showed no significant difference between the groups (any intervention for GERDvs placebo for cough resolution; OR, 1.14; 95% CI, 0.45-2.93;P¼.78). Proton pumpinhibitors (vs placebo) caused increased serious adverse events. Qualitative data fromexisting CHEST cough systematic reviews were consistent with two international GERDguidelines.CONCLUSIONS:The panelists endorsed that: (1) treatment(s) for GERD should not be usedwhen there are no clinical features of GERD; and (2) pediatric GERD guidelines should beused to guide treatment and investigations.]]> Fri 19 May 2023 09:55:59 AEST ]]>